Antonino C Tralongo

Dr. Antonino C Tralongo


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 October 2020 in Internal and Emergency Medicine
Verified
Journal Article
Closed access
PDF file
FCFrancesca Caspani
Francesca Caspani
ATAntonino C Tralongo
Antonino C Tralongo
LCLeonardo Campiotti
Leonardo Campiotti
RARiccardo Asteggiano
Riccardo Asteggiano
LGLuigina Guasti
Luigina Guasti
ASAlessandro Squizzato
Alessandro Squizzato

17 April 2024 in Journal of Endocrinological Investigation
Verified
Journal Article
Closed access
PDF file
MCMarco Chianelli
Marco Chianelli
Luca BusettoLuca Busetto
Luca Busetto
RVRoberto Vettor
Roberto Vettor
BABruno Annibale
Bruno Annibale
APA. Paoletta
A. Paoletta
RARoberto Attanasio
Roberto Attanasio

15 June 2020 in Tumori Journal
Verified
Journal Article
Closed access
PDF file
ATAntonino C Tralongo
Antonino C Tralongo
AAAndrea Antonuzzo
Andrea Antonuzzo
PPPaolo Pronzato
Paolo Pronzato
ASAndrea Sbrana
Andrea Sbrana
MTMarianna Turrini
Marianna Turrini
MDMarco Danova
Marco Danova
Neutropenia is the most frequent side effect of commercially available myelosuppressive drugs and its most significant complication is febrile neutropenia. It is associated with increased hospital admissions and higher probability of death. Prophylaxis with the administration of granulocyte colony-stimulating factor can prevent neutropenia caused by anticancer drugs. The correct administration of these drugs and the management of febrile neutropenia are extremely important in the treatment of patients with cancer.

2 June 2020 in Tumori Journal
Verified
Journal Article
Closed access
PDF file
ASAndrea Sbrana
Andrea Sbrana
AAAndrea Antonuzzo
Andrea Antonuzzo
ABAntonella Brunello
Antonella Brunello
FPFausto Petrelli
Fausto Petrelli
PPPaolo Pronzato
Paolo Pronzato
MDMarco Danova
Marco Danova
This article summarizes the latest Italian Medical Oncology Association (AIOM) guidelines on the management of cancer-related and chemotherapy-related anemia with a particular attention to the use of erythropoiesis-stimulating agents and iron supplementation.

15 April 2021 in Geriatrics
Verified
Journal Article
Open access
PDF file
ATAntonino C Tralongo
Antonino C Tralongo
RFRoberto S. Fratamico
Roberto S. Fratamico
CRChiara Russo
Chiara Russo
ASAndrea Sbrana
Andrea Sbrana
AAAndrea Antonuzzo
Andrea Antonuzzo
MDMarco Danova
Marco Danova
Aging is a well-recognized risk factor for the development of cancer. The incidence of new cancer diagnoses has increased globally given the rising senior population. Many hypotheses for this increased risk have been postulated over decades, including increased genetic and epigenetic mutations and the concept of immunosenescence. The optimal treatment strategies for this population with cancer are unclear. Older cancer patients are traditionally under-represented in clinical trials developed to set the standard of care, leading to undertreatment or increased toxicity. With this background, it is crucial to investigate new opportunities that belong to the most recent findings of an anti-cancer agent, such as immune-checkpoint inhibitors, to manage these daily clinical issues and eventually combine them with alternative administration strategies of antiblastic drugs such as metronomic chemotherapy.

14 November 2025 in ESMO Open
Verified
Journal Article
Open access
FSFrancesca Spada
Francesca Spada
FGFabio Gelsomino
Fabio Gelsomino
MRM. Rinzivillo
M. Rinzivillo
MCM. Cinquini
M. Cinquini
VFV.A. Fittipaldo
V.A. Fittipaldo
NFNicola Fazio
Nicola Fazio
Neuroendocrine neoplasms (NENs) of the gastroenteropancreatic (GEP) tract represent a rare and heterogeneous group of malignancies. They are distinguished into well-differentiated and poorly differentiated neoplasms, with clinical behavior ranging from relatively indolent to fast-growing, respectively. Surgery is the curative option for localized disease, especially in well-differentiated neoplasms, while various systemic therapies are approved and clinically available for advanced disease. However, considering the complexity of these malignancies, the choice of therapeutic strategy must take into account multiple factors, such as histological diagnosis, primary site, extent of disease, evolution features, functional status, patients and treatment characteristics, treatment availability, and safety profile. A multidisciplinary approach dedicated to NENs and conducted by experienced teams is therefore strongly recommended. Since 2013, the Italian Association of Medical Oncology (AIOM), in collaboration with the Italian Association for Neuroendocrine Tumors (ITANET), has produced guidelines using the Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) approach for assessing the certainty of evidence. This updated version (2024) summarized the main diagnostic and therapeutic decision-making processes on specific topics selected by a panel of experts from the AIOM, ITANET, and other national scientific societies with the aim of guiding clinicians in the diagnosis, treatment, and monitoring of patients with GEP-NENs. The integration of these guidelines into daily clinical practice is expected to improve patient care and drive the evolving landscape of GEP-NEN management.